Huang Nai-Si, Chen Jia-Ying, Meng Yan, Li Qiu-Li, Ji Qing-Hai, Wang Yu
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
Department of Oncology, Hainan Cancer Hospital, Haikou, China.
Oral Oncol. 2024 Dec;159:107014. doi: 10.1016/j.oraloncology.2024.107014. Epub 2024 Sep 21.
5-10% of thyroid cancers are at locally advanced stage. Neoadjuvant targeted therapy will likely create surgical opportunities for these patients with unresectable or borderline resectable tumors. Pralsetinib, a RET inhibitor, has been approved for advanced or metastatic RET-altered thyroid cancer. However, there is no evidence on the efficacy of pralsetinib as neoadjuvant therapy in locally advanced RET-altered thyroid cancer.
Two patients with locally advanced pappilary thyroid carcinoma (PTC) were treated with pralsetinib (400 mg daily) to reduce tumor size and increase the chance of R0 resection. Both PTCs, characterized by RET-fusion, underwent successful R0 resection without major surgical complications after 4-months neoadjuvant pralsetinib.
There is a potential for pralsetinib as a neoadjuvant treatment in PTC with RET-fusion.
5% - 10%的甲状腺癌处于局部晚期。新辅助靶向治疗可能为这些患有不可切除或临界可切除肿瘤的患者创造手术机会。普拉替尼是一种RET抑制剂，已被批准用于治疗晚期或转移性RET改变的甲状腺癌。然而，尚无证据表明普拉替尼作为新辅助治疗在局部晚期RET改变的甲状腺癌中的疗效。
两名局部晚期乳头状甲状腺癌（PTC）患者接受了普拉替尼（每日400毫克）治疗，以缩小肿瘤大小并增加R0切除的机会。这两例均为RET融合特征的PTC，在接受4个月的新辅助普拉替尼治疗后，均成功进行了R0切除，且无重大手术并发症。
普拉替尼作为RET融合的PTC新辅助治疗具有潜力。
